These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11364818)

  • 1. Half-full or half-empty: no simple answer on protease inhibitor failure.
    Torres G
    GMHC Treat Issues; 1997 Oct; 11(10):1-2. PubMed ID: 11364818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virologic failure and salvage therapy.
    HIV Hotline; 1998 Mar; 8(1):2-3. PubMed ID: 11365357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
    Lichterfeld M; Wöhrmann A; Schmeisser N; Fätkenheuer G; Salzberger B; Wyen C; Schmitz K; Sauerbruch T; Rockstroh JK
    Eur J Med Res; 2003 Feb; 8(2):56-60. PubMed ID: 12626282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue me.
    Simmons P
    Res Initiat Treat Action; 1998 Aug; 4(5):10. PubMed ID: 11365705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICAAC and Hamburg: Part 1. Schmuddelwetter or, rating protease inhibitors on the pass/fail system.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Dec; 3(12):29-37. PubMed ID: 11364943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):17-21. PubMed ID: 11364427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease inhibitors: resistance, resistance, resistance.
    Gilden D; Falkenberg J; Torres G
    GMHC Treat Issues; 1997 Feb; 11(2):5-10. PubMed ID: 11364108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplifying drug regimens.
    HIV Hotline; 1998 Mar; 8(1):11. PubMed ID: 11365353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term strategies: should some patients wait to start protease inhibitors? Interview with Keith Henry, M.D. Interview by John S. James.
    Henry K
    AIDS Treat News; 1997 Oct; (No 281):1, 3-6. PubMed ID: 11364791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trials for protease failure.
    Posit Aware; 1998; 9(5):16-7. PubMed ID: 11365884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
    Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
    HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conference updates show promising drug data.
    AIDS Alert; 1997 Nov; 12(11):125-6. PubMed ID: 11364769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.
    Nieuwkerk P; Gisolf E; Sprangers M; Danner S;
    Antivir Ther; 2001 Jun; 6(2):97-103. PubMed ID: 11491422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for protease inhibitor failure.
    Proj Inf Perspect; 1997 Nov; (23):4-5. PubMed ID: 11365379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.